Group items tagged

Opioids agonist drugs are a group of powerful and widely used drugs that alleviate the pain of moderate to severe chronic pain by reducing the impact of narcotic receptors in the brain. These include both codeine and hydrocodone, the most common opioids. Although they relieve pain, they have serious side effects that include drowsiness, respiratory depression, dizziness, nausea, and sweating. These drugs are very powerful, so overdoses are common, and death from them is even more common. This group of drugs has received heavy criticism from both patients and doctors alike for the risks involved in using them. The opioid antagonist hydrocodone works by blocking the opioid receptors in the body. Codeine is the only opioid that does this in a pure form. Because hydrocodone blocks the opioid receptors in the brain, it becomes less available to people who take it. This opioid group is popular among heroin abusers, since heroin creates a euphoric state that cannot be reproduced with hydrocodone. For this reason, heroin abusers frequently turn to other forms of treatment, such as prescription medications and methadone. Other opioids agonist drugs in this group include oxycodone, hydromorphone (Percoset), hydromorphone hydrochloride (hydrocodone), and methadone. Taking them is not without dangers though. Oxycodone has caused at least five deaths and several dozen hospital admissions in the US since 1999. In extremely rare cases, people have died of overdosing on hydrocodone. Heroin abusers also regularly take this drug, since it can suppress their desire for heroin. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2021/02/emergence-of-covid-19-and-increasing.html

Opioid-induced constipation (OIC) is caused by prolonged use of certain opioids, particularly for pain management. OIC may also be caused by taking long-term and excessive doses of narcotics with effects similar to dehydration, constipation, or nausea. OIC is a common condition affecting individuals with long-standing or steady use of powerful prescription pain medications like OxyContin, codeine and morphine, as well as individuals who take sedatives frequently or individuals who have other conditions like diarrhea, kidney or liver disease, or Crohn's disease. Approval and launch of new products is expected to propel growth of the Opioid Induced Constipation Treatment Market. For instance, in September 2020, Sandoz, the generics division of Novartis AG, received a positive reimbursement decision in the UK for Rizmoic (naldemedine). The National Institute for Health and Care Excellence, U.K., issued a recommendation in favor of the option for treating opioid-induced constipation in adults, after previous laxative treatment. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/approval-and-launch-of-new-products-and.html